| Literature DB >> 24965758 |
Xiaoxuan Liu1, Cheng Liu2, Chao Chen3, Mélanie Bentobji4, Francine Azario Cheillan4, Jeanne Thomassin Piana4, Fanqi Qu5, Palma Rocchi6, Ling Peng7.
Abstract
Small interfering RNAs (siRNA) are emerging as novel therapeutic agents, providing competent delivery systems that are available. Dendrimers, a special family of synthetic macromolecules, represent an exciting delivery platform by virtue of their well-defined dendritic structure and unique multivalency and cooperativity confined within a nanoscale volume. Here, we report a Dicer-substrate siRNA (dsiRNA) which, when delivered using a structurally flexible triethanolamine-core poly(amidoamine) dendrimer of generation 5 as the nanocarrier, gives rise to a much greater RNAi response than that produced with conventional siRNA. Further decoration of the dsiRNA/dendrimer complexes with a dual targeting peptide simultaneously promoted cancer cell targeting through interacting with integrins and cell penetration via the interaction with neuropilin-1 receptors, which led to improved gene silencing and anticancer activity. Altogether, our results disclosed here open a new avenue for therapeutic implementation of RNAi using dendrimer nanovector based targeted delivery. FROM THE CLINICAL EDITOR: This study demonstrates superior therapeutic properties of siRNA when combined with a dendrimer-based targeted nano-delivery system. Similar approaches may eventually gain clinical utility following additional studies determining safety and efficacy.Entities:
Keywords: Dendrimer; Nanovector; Prostate cancer; Targeted delivery; siRNA
Mesh:
Substances:
Year: 2014 PMID: 24965758 DOI: 10.1016/j.nano.2014.05.008
Source DB: PubMed Journal: Nanomedicine ISSN: 1549-9634 Impact factor: 5.307